Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.27), $0.08 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $57.6 million versus the consensus estimate of $49.84 million.

"As patient and physician demand for Cologuard continues to grow, momentum is increasing toward Cologuard becoming part of the standard of care in colon cancer screening," said Kevin Conroy, chairman and CEO of Exact Sciences. "We will continue investing in the long-term and sustainable growth of Cologuard to ensure the millions of people who need to be screened for colon cancer have access to our non-invasive test."

Updated 2017 Outlook

• The company anticipates revenue of $230-240 million and completed Cologuard test volume of at least 550,000 tests during 2017.
• The company's previous guidance was $195-205 million in revenue and at least 470,000 completed Cologuard tests.
• The company anticipates completing at least 150,000 Cologuard tests during the third quarter of 2017.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.